Program description
This annual event brings together experts in the field of hematologic malignancies to debate and discuss advances in treatment for these cancers, novel treatment options, and debate current treatment paradigms. There is a mini session focusing on the management of immunotherapy and its use in solid tumors as well.
Target audience
This educational activity is designed for medical oncologists, hematologists, radiation oncologists, surgical oncologists, pharmacists, nurse practitioners, physician assistants, fellows, nurses and other health care professionals interested in the treatment of patients with hematologic malignancies.
Learning outcomes
- Describe emerging data and recent advances in the management of both malignant and benign hematologic disease
- Examine the use of immunotherapy in the management of solid tumors
- Compare traditional and emerging treatment options in the management of hemato- logic disease
- Examine the decision making strategies considered in the management of multiple myeloma including choosing the optimal induction regimen, the role of immunothera- py and the management of refractory disease
- Discuss the role and economics of CAR-T in the cancer population
Schedule
Friday, April 29, 2022
12:00 p.m. Registration Opens
12:55 p.m. Welcome and Introductions: Joseph Moore, MD
Session 1: Applying Immunotherapy in Your Clinic Today!
Moderator: H. Kim Lyerly, MD
1:00 p.m. Pre-session Survey
1:05 p.m. The Use of Immunotherapy in Breast Cancer (H. Kim Lyerly, MD)
1:45 p.m. The Use of Immunotherapy in Lung Cancer (Scott Antonia, MD)
2:25 p.m. Break and Product Theater #1
3:05 p.m. The Use of Immunotherapy in Colon Cancer (David Hsu, MD, PhD)
3:45 p.m. Immunotherapy Mediated Endocrinopathies in Cancer (Afreen Shariff, MD)
4:00 p.m. Product Theater #2
Saturday, April 30, 2022
7:00 – 7:45 a.m. Registration and Breakfast
Session 2: Leukemias / MPNs
Moderator: Harry Erba, MD, PhD
7:45 a.m. Welcome and Pre-Session Survey
8:00 a.m. Debate: FDOACs are Inadequate for Prophylaxis and Treatment of COVID-19 Coagulopathy (Thomas Ortel, MD vs. David Miller, MD (Novant))
8:40 a.m. Debate: Oral decitabine Should be Used as Initial Therapy for all Patients with Intermediate and High Risk Myelodysplastic Syndromes? (Guillermo Garcia Manero (MD Anderson) vs. Mikkael Sekeres, MD, MS (U of Miami))
9:20 a.m. Break and Product Theater #3
10:00 a.m. Debate: Chronic Phase CML Patients Not Achieving Response Milestones in the First 12 Months of ABL TKI Therapy Should be Switched to asciminib (ABL-001) (Jorge Cortes, MD (Georgia Cancer Center) vs Jerald Radich, MD (Fred Hutch))
10:40 a.m. Debate: HMA/Venetoclax combinations are now the Treatment of Choice for all Older AML Patients Regardless of Fitness (Eytan Stein, MD (MSKCC) (Virtual) vs. Harry Erba, MD, PhD)
11:20 a.m. Debate: BTK vs BCL2 inhibitors in the relapsed or refractory setting of CLL (Danielle Brander, MD vs. Alan Skarbnik, MD (Novant))
12:00-1:00 p.m. Lunch and Time with Exhibitors and Product Theater #4
Session 3: Lymphomas
Moderator: Danielle Brander, MD
1:00 p.m. Pre-Session Survey
1:05 p.m. Debate: The Economics of CAR-T Make it Feasible to Expand to the General Cancer Population as First Salvage (Scott Huntington, MD, MPH, MSc (Yale) vs. Jie Wang, MD)
1:45 p.m. Debate: BTK Inhibitors Should be First Line Therapy Rather Than Chemotherapy for Waldenstrom’s/LPL (Matthew McKinney, MD vs. Alexandra Stefanovic, MD)
2:25 p.m. Break and Product Theater #5
3:05 p.m. Debate: Relapsed Follicular Lymphoma Can Continue to Benefit from Chemoimmunotherapy/Immunotherapy and Continuous Novel/Targeted Agents Should be Reserved for Later (Anne Beaven, MD, vs. Matthew McKinney, MD)
3:45 p.m. How I Treat: Updates on New Approaches to PNH (Carlos DeCastro, MD)
4:25 p.m. Post-Session Survey and Adjourn
Sunday, May 1, 2022
7:00 – 7:45 a.m. Registration and Breakfast
7:45 a.m. Welcome
8:00 a.m. Pre-Session Survey
Session 4: Hematology
Moderator: Cristiana Costa, MD
8:10 a.m. Debate: Optimal Management of Penta-refractory Myeloma: selinexor vs. belantamab (Yubin Kang, MD vs. Cristina Gasparetto, MD)
8:50 a.m. Break and Product Theater #3
9:30 a.m. Myeloma Case Based Audience Response Session (Cristiana Costa Chase, DO Panel: Costa, Gasparetto, Kang)
Is Consolidation Therapy Post Autologous Transplant Needed?
Choosing the Optimal Induction Regimen
What is the role of Immunotherapy/CAR-T in MM
11:15 a.m. Q&A and Post-Session Survey
11:30 a.m. Adjourn
Special Thanks to our Platinum Sponsors
Genentech, Incyte and Janssen
Gold Sponsors
Abbvie and Bristol-Myers Squibb
Silver Sponsors
AstraZeneca, Takeda
Bronze Sponsors
Amgen, Jazz, Sanofi Genzyme
2020 Educational Grant Supporter
Dova
Exhibitors
Agios, Alexion, Kite, Karyopharm, Kyowa Kirin, Novartis
Program Chair
David Rizzieri, MD, Professor of Medicine
Committee Members
Danielle Brander, MD, Assistant Professor of Medicine
Cristina Gasparetto, MD, Professor of Medicine
Joe Moore, MD, Professor of Medicine
Linda Sutton, MD, Associate Professor of Medicine
Honored Guest Faculty
Shruti Chaturvedi, MBBS, MS , Assistant Professor of Medicine, Johns Hopkins University School of Medicine
Jonathon Cohen, MD, MS, Associate Professor, Emory University, Winship Cancer Institute
Daniel DeAngelo, MD, PhD, Chief of the Division of Leukemia, Dana Farber Cancer Institute
Scott Huntington, MD, MPH, MSc, Assistant Professor of Medicine, Yale University; Medical Director, Hematology Outpatient Program, Smilow Cancer Hospital
John Pagel, MD, PhD, Chief of Hematologic Malignancies, Swedish Cancer Institute
Josef Prchal, MD, Professor of Medicine, The University of Utah, Salt Lake City
Ronan Swords, MD, PhD, FRCPI, PRCPath, Medical Director, AbbVie
Dan Weisdorf, MD, Professor of Medicine, University of Minnesota
Duke Faculty
Gowthami Arepally, MD, Professor of Medicine
Carlos DeCastro, MD, Professor of Medicine
Ahmed Galal, MD, Professor of Medicine
David Hsu, MD, PhD, Associate Professor of Medicine
Christopher Kelsey, MD, Associate Professor of Radiation Oncology
Anand Lagoo, MD, PhD, Professor of Pathology
H. Kim Lyerly, MD, Professor of Surgery, Professor of Immunology, Professor of Pathology
Chad McCall, MD, PhD, Assistant Professor of Pathology
Dina Randazzo, DO, MS, Assistant Professor of Neurosurgery
Lindsay Rein, MD, Assistant Professor of Medicine
Nirmish Shah, MD, Associate Professor of Medicine
Andrea Sitlinger, MD, Medical Instructor, Department of Medicine
Alexandra Stefanovic, MD, Associate Professor of Medicine
John J. Strouse, MD, PhD, Associate Professor of Medicine and Pediatrics
Jie Wang, MD, MS, Medical Instructor, Department of Medicine
Joint Accreditation Statement
In support of improving patient care, the Duke University Health System Department of Clinical Education and Professional Development is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the health care team.
Successful completion of this activity, which includes participation in the evaluation com- ponent, enables the participant to earn up to 14.75 MOC Part 2 points [and patient safety MOC credit] in the American Board of Internal Medicine’s (ABIM) Maintenance of Certifica- tion (MOC) program. Participants will earn MOC points equivalent to the amount of credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Credit Statement
Physicians: Duke University Health System Department of Clinical Education and Profes- sional Development designates this live activity for a maximum of 14.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Nursing: Duke University Health System Department of Clinical Education and Professional Development designates this activity for up to 14.75 credit hours for nurses. Nurses should claim only credit commensurate with the extent of their participation in this activity.
Pharmacists: Duke University Health System Department of Clinical Education and Profes- sional Development designates this activity for up to 14.75 ACPE credit hours. Universal Activity Numbers: JA000655-0000-20-258-L01-P
Special Needs Statement
The Duke Cancer Network is committed to making its activities accessible to all individuals. If you are in need of an accommodation, please do not hesitate to call and/or submit a description of your needs in writing in order to receive service.